Biomedical Research Education & Training
Faculty Member

Mayer, Ingrid A., M.D.
Associate Professor of Medicine

Lab Url: http://medicine.mc.vanderbilt.edu/divisions/hemonc/search_kaiser2.cfm?PI=1305

Phone Number: (615) 322-4967

Email Address: ingrid.mayer@vanderbilt.edu

Mayer, Ingrid's picture
Academic history
Doctor of Medicine (M.D), Federal University of Sao Paulo, Brazil
Internal Medicine Residency, University of Illinois at Chicago
Internal Medicine Chief Residency, University of Illinois at Chicago
Hematology/ Oncology Fellowship, University of Illinois at Chicago
Master of Science in Clinical Investigation (M.S.C.I.), Vanderbilt University School of Medicine

Office Address   Mailing Address

790 PRB Vanderbilt - Ingram Cancer Center; 2220 Pierce Avenue, Nashville, TN 37232

Vanderbilt - Ingram Cancer Center 777 Preston Research Building 37232


Research Keywords
Breast Cancer - Targeted Therapies,Cancer,Translation

Clinical Research Keywords
Breast Cancer - Targeted Therapies

Patient Care Specialty
Medical Oncology - Breast Cancer

Research Description
Dr. Mayer research endeavors have been focused on 1) the identification of targetable pathways in breast cancer, 2) ErbB signaling and endocrine therapy resistance in estrogen receptor positive (ER+) breast cancers, 3) PI3K signaling and endocrine therapy resistance in ER+ breast cancers, 4) chemotherapy resistance in triple negative breast cancers, and 5) biomarker prediction of treatment response in human breast cancers.
Identification of targetable pathways in breast cancer. To enhance understanding of breast cancer biology and to elucidate molecular determinants of clinical efficacy, Dr. Mayer obtained a Vanderbilt Physician Scientist Development (VPSD) Award. The specific aims of this grant were to identify relevant tumor antigens by multidimensional liquid chromatography (LC) and tandem mass spectrometry (MS) using antibodies raised against specific peptide motifs recognized by circulating IgGs in breast cancer patients sera and to determine if these tumor antigens could be detected by immunohistochemistry in all different subsets of primary breast tumors. Preliminary results of this work led to testing of new therapeutic strategies targeting the phosphatidylinositol-3 kinase (PI3K)/Akt and correlated pathways in triple-negative, hormone-refractory and HER2-overexpressing refractory breast cancers, using biologically-based targeted agents. Initially, Dr. Mayer conducted a pilot project to determine the safety of an oral mTOR inhibitor in combination with an EGFR inhibitor in patients with metastatic breast cancer, addressing the synergism between EGFR and PI3K pathways. This study was partially funded by a Breast Cancer SPORE Pilot Project Grant. The outcome from this pilot project served as the preliminary data for her K23 Career Development Award. This grant included molecular analysis of individual breast cancers to determine how the biology of the cancer affects the response to the therapeutic agent.
ErbB signaling and endocrine therapy resistance in ER+ breast cancers. Preclinical models and some clinical observations suggest that ER+ breast cancers initially inhibited by a selective estrogen-receptor modulator (SERM) can use autocrine ErbB signaling in order to escape SERM action. This mechanism involves crosstalk between growth factor signaling and ER. Dr. Mayer obtained a Breast Cancer Research Foundation American Association for Cancer Research (BCRF-AACR) Grant for Translational Breast Cancer Research to explore if clinically combining an aromatase inhibitor with an EGFR/HER2 inhibitor would restore sensitivity to endocrine treatment in ER+/HER2+ breast cancers and would prevent the emergence of cells resistant to endocrine therapy. As a continuation of this work, funds were also obtained through the Breast Cancer Specialized Program of Research Excellence (SPORE), Project 1 to determine 1) if combined neoadjuvant breast cancer therapy with the aromatase inhibitor letrozole and the HER2 tyrosine kinase inhibitor lapatinib induces pathologic complete responses in hormone receptor-positive breast cancers that overexpress HER2 and 2) to establish biomarkers predictive of response to this therapy, 3) to determine if the post-letrozole Ki67 in hormone receptor-positive/HER2-negative tumors mirrored the recurrence score as measured by RT-PCR of 21 selected genes in formalin-fixed tumor tissue sections, and 4) to use these biomarkers to discover gene expression signatures associated with response or resistance to estrogen deprivation.
PI3K signaling and endocrine therapy resistance in ER+ breast cancers. Preclinical and a few clinical studies have already suggested that ER+/PI3K mutant tumors exhibit a lower response to antiestrogens compared to ER+/PI3K wild-type tumors. Upon recent renewal of the Breast Cancer Specialized Program of Research Excellence (SPORE), Project 1, Dr. Mayer is seeking to explore if the combination of antiestrogens with a PI3K inhibitor would be more effective against ER+/PI3K mutant breast cancers compared to the antiestrogen alone. In addition, breast cancers that do not respond to the combination will be tested for somatic alterations causally associated with drug resistance through whole exome sequencing. Based on Dr. Mayer active role in this area, she was invited to be the lead investigator in three clinical trials being run through the SU2C Dream Team Targeting PI3K in Women Cancers Grant, which focuses on determining the role of PI3K pathway in breast, ovarian and endometrial cancers. Dr. Mayer spearheaded two phase Ib discovery trials, that addressed the combination of antiestrogen therapy with 3 different PI3K inhibitors, and one global phase II randomized demonstration trial that addresses the randomized combination of antiestrogen therapy with 2 different PI3K inhibitors. The latter trial is highly innovative due to the genotype specific nature of the trial. Chemotherapy resistance in triple-negative breast cancers (TNBC). In collaboration with Dr. Jennifer Pietenpol, Dr. Mayer explored novel targets to address chemotherapy resistance in TNBC. TNBC is an aggressive form of breast cancer for which to date, not a single targeted therapy has been approved and where cytotoxic chemotherapy remains a sub-optimal standard treatment. Dr. Mayer obtained funds through the Breast Cancer Specialized Program of Research Excellence (SPORE), Project 2 to determine the degree of tumor response to neoadjuvant cisplatin, paclitaxel, and the TOR inhibitor everolimus (RAD001) versus cisplatin and paclitaxel therapy in patients with TNBC. In the context of this trial, tissues were analyzed to explore 1) if gene expression profiling could sub-classify triple negative, basal-like cancers and 2) to identify gene expression signatures, such as those of p63 and p73, which would predict sensitivity and response to neoadjuvant, preoperative therapy in triple negative breast cancers. Biomarker prediction of treatment response in human breast cancers. Noninvasive imaging techniques such as MRI and PET provide uniquely valuable information for the diagnosis and management of cancer and potentially have an important role in predicting the response of individual tumors to targeted treatment. Preoperative chemotherapy has become an attractive model for trials assessing surrogate markers of response or resistance to therapy. Imaging markers have potential to determine which patient should initiate or continue therapy and who should be recommended an alternate treatment. Dr. Mayer has been a key co-investigator/collaborator on over 5 NIH, DoD, or Foundation grants throughout the institution, particularly in collaboration with investigators from the Department of Chemical Biology, the Vanderbilt Imaging Sciences Division, and the Cardiology Division on grants and trials that aim to develop specific guidelines for incorporating optimized and integrated quantitative PET-MRI into appropriate clinical trials. The goal is to provide a sensitive and robust method to separate responders and non-responders within the first two cycles of treatment. Such knowledge would allow for the early tailoring of individualized therapy.

Clinical Research Description
1- Identification of targetable pathways in breast cancer. Dr. Mayer obtained a Vanderbilt Physician Scientist Development (VPSD) Award to test new therapeutic strategies targeting the phosphatidylinositol-3 kinase (PI3K)/Akt and correlated pathways in breast cancers, using biologically-based targeted agents. Initially, Dr. Mayer conducted a pilot project to determine the safety of an oral mTOR inhibitor in combination with an EGFR inhibitor in patients with metastatic breast cancer, addressing the synergism between EGFR and PI3K pathways. This study served as the preliminary data for her K23 Career Development Award.
2- ErbB signaling and endocrine therapy resistance in ER+ breast cancers. Dr. Mayer obtained a Breast Cancer Research Foundation ??? American Association for Cancer Research (BCRF-AACR) Grant for Translational Breast Cancer Research to explore if clinically combining an aromatase inhibitor with an EGFR/HER2 inhibitor would restore sensitivity to endocrine treatment in ER+/HER2+ breast cancers and would prevent the emergence of cells resistant to endocrine therapy. Funds were also obtained through the Breast Cancer Specialized Program of Research Excellence (SPORE), Project 1 to determine 1) if combined neoadjuvant breast cancer therapy with the aromatase inhibitor letrozole and the HER2 tyrosine kinase inhibitor lapatinib induces pathologic complete responses in hormone receptor-positive breast cancers that overexpress HER2 and 2) to establish biomarkers predictive of response to this therapy, 3) to determine if the post-letrozole Ki67 in hormone receptor-positive/HER2-negative tumors mirrored the recurrence score as measured by RT-PCR of 21 selected genes in formalin-fixed tumor tissue sections, and 4) to use these biomarkers to discover gene expression signatures associated with response or resistance to estrogen deprivation.
3- PI3K signaling and endocrine therapy resistance in ER+ breast cancers. Within the Breast Cancer Specialized Program of Research Excellence (SPORE), Project 1, Dr. Mayer is seeking to explore if the combination of antiestrogens with a PI3K inhibitor would be more effective against ER+/PI3K mutant breast cancers compared to the antiestrogen alone. Based on Dr. Mayer's active role in this area, she was invited to be the lead investigator in three clinical trials being run through the SU2C Dream Team Targeting PI3K in Women???s Cancers, which focuses on determining the role of PI3K pathway in breast, ovarian and endometrial cancers.
4- Chemotherapy resistance in triple-negative breast cancers (TNBC). Dr. Mayer obtained funds through the Breast Cancer Specialized Program of Research Excellence (SPORE), Project 2 to determine the degree of tumor response to neoadjuvant cisplatin, paclitaxel, and the TOR inhibitor everolimus (RAD001) versus cisplatin and paclitaxel therapy in patients with TNBC. In the context of this trial, tissues were analyzed to explore 1) if gene expression profiling could sub-classify triple negative, basal-like cancers and 2) to identify gene expression signatures, such as those of p63 and p73, which would predict sensitivity and response to neoadjuvant, preoperative therapy in TNBC.
5- Biomarker prediction of treatment response in human breast cancers. Dr. Mayer has been a key co-investigator/collaborator on over 5 NIH, DoD, or Foundation grants throughout the institution, particularly in collaboration with investigators from the Department of Chemical Biology, the Vanderbilt Imaging Sciences Division, and the Cardiology Division on grants and trials that aim to develop specific guidelines for incorporating optimized and integrated quantitative PET-MRI into appropriate clinical trials.

Clinical Interests
Dr. Mayer is a medical oncologist that specializes in breast cancer. Along with Dr. Ingrid Meszoely (Surgical Oncology, Breast Center Director), they fostered the creation of a Breast Cancer Multidisciplinary Clinic in 2007 at the Vanderbilt Breast Center at the Village at Vanderbilt, which allowed new patients to see a medical oncologist, a surgical oncologist and a radiation oncologist all during the same visit. As Medical Oncology director of the Breast Center, Dr. Mayer supervises the clinical operation of the Medical Oncology clinic (including the breast cancer research team operation at OHO) and is the liaison between Medical Oncology and Imaging and Surgical services at the Breast Center. Dr. Mayer attends two full days a week in the breast cancer outpatient oncology clinic, and provides day-to-day oversight of the medical oncology outpatient care at the Vanderbilt Breast Center at OHO, as Medical Oncology director. From a clinical standpoint, Dr. Mayer is regarded as one of the leading breast cancer oncologists not only at Vanderbilt but nationally. She sees breast cancer patients referred from throughout the southeastern United States and sometimes beyond. For several years now, she has annually received the Five Star Awards in the Excellence in Healthcare and has been selected as one of the "Best Doctors in America" by US News Top Doctors.

Publications
Abramson, VG, Cooper Lloyd, M, Ballinger, T, Sanders, ME, Du, L, Lai, D, Su, Z, Mayer, I, Levy, M, LaFrance, DR, Vnencak-Jones, CL, Shyr, Y, Dahlman, KB, Pao, W, Arteaga, CL. Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling. Breast Cancer Res Treat, 145(2), 389-99, 2014

Johnson, DB, Dahlman, KH, Knol, J, Gilbert, J, Puzanov, I, Means-Powell, J, Balko, JM, Lovly, CM, Murphy, BA, Goff, LW, Abramson, VG, Crispens, MA, Mayer, IA, Berlin, JD, Horn, L, Keedy, VL, Reddy, NM, Arteaga, CL, Sosman, JA, Pao, W. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist, 19(6), 616-22, 2014

Lenneman, CG, Abdallah, WM, Smith, HM, Abramson, V, Mayer, IA, Silverstein, C, Silverstein, C, Means-Powell, J, Paranjape, SY, Lenihan, D, Sawyer, DB, Raj, SR. Sympathetic nervous system alterations with HER2+ antagonism: an early marker of cardiac dysfunction with breast cancer treatment. Ecancermedicalscience, 8, 446, 2014

Li, X, Arlinghaus, LR, Ayers, GD, Chakravarthy, AB, Abramson, RG, Abramson, VG, Atuegwu, N, Farley, J, Mayer, IA, Kelley, MC, Meszoely, IM, Means-Powell, J, Grau, AM, Sanders, M, Bhave, SR, Yankeelov, TE. DCE-MRI analysis methods for predicting the response of breast cancer to neoadjuvant chemotherapy: pilot study findings. Magn Reson Med, 71(4), 1592-602, 2014

Mayer, IA, Abramson, VG, Isakoff, SJ, Forero, A, Balko, JM, Kuba, MG, Sanders, ME, Yap, JT, Van den Abbeele, AD, Li, Y, Cantley, LC, Winer, E, Arteaga, CL. Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol, 32(12), 1202-9, 2014

Mayer, IA, Abramson, VG, Lehmann, BD, Pietenpol, JA. New strategies for triple-negative breast cancer--deciphering the heterogeneity. Clin Cancer Res, 20(4), 782-90, 2014

Mayer, IA, Arteaga, CL. PIK3CA Activating Mutations: A Discordant Role in Early Versus Advanced Hormone-Dependent Estrogen Receptor-Positive Breast Cancer. J Clin Oncol, 2014

Yamaguchi, NH, Mayer, IA, Malzyner, A, de Andrade, CJ, Murad, AM, Del Giglio, A, Alves, V. Gefitinib and celecoxib in advanced metastatic gastrointestinal tumors: a pilot feasibility study. J Gastrointest Oncol, 5(1), 57-66, 2014

Castel, LD, Hartmann, KE, Mayer, IA, Saville, BR, Alvarez, J, Boomershine, CS, Abramson, VG, Chakravarthy, AB, Friedman, DL, Cella, DF. Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort. Cancer, 119(13), 2375-82, 2013

Geisberg, CA, Abdallah, WM, da Silva, M, Silverstein, C, Smith, HM, Abramson, V, Mayer, I, Means-Powell, J, Freehardt, D, White, B, Lenihan, D, Sawyer, DB. Circulating neuregulin during the transition from stage A to stage B/C heart failure in a breast cancer cohort. J Card Fail, 19(1), 10-5, 2013

Iams, W, Beckermann, KE, Neff, AT, Mayer, IA, Abramson, VG. Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case report. Med Oncol, 30(2), 568, 2013

Mayer, I. Role of mTOR inhibition in preventing resistance and restoring sensitivity to hormone-targeted and HER2-targeted therapies in breast cancer. Clin Adv Hematol Oncol, 11(4), 217-24, 2013

Mayer, IA. Subtyping of triple-negative breast cancer. Clin Adv Hematol Oncol, 11(11), 731-2, 2013

Abramson, VG, Mayer, IA. Improving survival and limiting toxicity: latest advances in treating human epidermal growth factor receptor 2 overexpressing breast cancer. Ther Adv Med Oncol, 4(3), 139-47, 2012

Balko, JM, Mayer, IA, Sanders, ME, Miller, TW, Kuba, MG, Meszoely, IM, Wagle, N, Garraway, LA, Arteaga, CL. Discordant cellular response to presurgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification. Mol Cancer Ther, 11(10), 2301-5, 2012

Li, X, Abramson, RG, Arlinghaus, LR, Chakravarthy, AB, Abramson, V, Mayer, I, Farley, J, Delbeke, D, Yankeelov, TE. An algorithm for longitudinal registration of PET/CT images acquired during neoadjuvant chemotherapy in breast cancer: preliminary results. EJNMMI Res, 2(1), 62, 2012

Li, X, Welch, EB, Chakravarthy, AB, Xu, L, Arlinghaus, LR, Farley, J, Mayer, IA, Kelley, MC, Meszoely, IM, Means-Powell, J, Abramson, VG, Grau, AM, Gore, JC, Yankeelov, TE. Statistical comparison of dynamic contrast-enhanced MRI pharmacokinetic models in human breast cancer. Magn Reson Med, 68(1), 261-71, 2012

Abramson, VG, Mayer, IA. Clinical utility of serum tumor markers and circulating tumor cell assays in the treatment of breast cancer. Curr Treat Options Oncol, 12(4), 403-11, 2011

Arlinghaus, LR, Welch, EB, Chakravarthy, AB, Xu, L, Farley, JS, Abramson, VG, Grau, AM, Kelley, MC, Mayer, IA, Means-Powell, JA, Meszoely, IM, Gore, JC, Yankeelov, TE. Motion correction in diffusion-weighted MRI of the breast at 3T. J Magn Reson Imaging, 33(5), 1063-70, 2011

Li, X, Welch, EB, Arlinghaus, LR, Chakravarthy, AB, Xu, L, Farley, J, Loveless, ME, Mayer, IA, Kelley, MC, Meszoely, IM, Means-Powell, JA, Abramson, VG, Grau, AM, Gore, JC, Yankeelov, TE. A novel AIF tracking method and comparison of DCE-MRI parameters using individual and population-based AIFs in human breast cancer. Phys Med Biol, 56(17), 5753-69, 2011

Bauer, JA, Chakravarthy, AB, Rosenbluth, JM, Mi, D, Seeley, EH, De Matos Granja-Ingram, N, Olivares, MG, Kelley, MC, Mayer, IA, Meszoely, IM, Means-Powell, JA, Johnson, KN, Tsai, CJ, Ayers, GD, Sanders, ME, Schneider, RJ, Formenti, SC, Caprioli, RM, Pietenpol, JA. Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Clin Cancer Res, 16(2), 681-90, 2010

Mayer, IA, Arteaga, CL. Does lapatinib work against HER2-negative breast cancers. Clin Cancer Res, 16(5), 1355-7, 2010

Carlson, RW, Allred, DC, Anderson, BO, Burstein, HJ, Carter, WB, Edge, SB, Erban, JK, Farrar, WB, Goldstein, LJ, Gradishar, WJ, Hayes, DF, Hudis, CA, Jahanzeb, M, Kiel, K, Ljung, BM, Marcom, PK, Mayer, IA, McCormick, B, Nabell, LM, Pierce, LJ, Reed, EC, Smith, ML, Somlo, G, Theriault, RL, Topham, NS, Ward, JH, Winer, EP, Wolff, AC, , . Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw, 7(2), 122-92, 2009

Li, X, Dawant, BM, Welch, EB, Chakravarthy, AB, Freehardt, D, Mayer, I, Kelley, M, Meszoely, I, Gore, JC, Yankeelov, TE. A nonrigid registration algorithm for longitudinal breast MR images and the analysis of breast tumor response. Magn Reson Imaging, 27(9), 1258-70, 2009

Mayer IA, Burris HA, Bendell JC, Means-Powell J, Arteaga CL, Shyr Y, Pietenpol JA. . A phase Ib trial of RAD001, an mTOR inhibitor, with weekly cisplatin and paclitaxel in patients with HER2-negative metastatic breast cancer.. 32nd Annual San Antonio Breast Symposium, San Antonio, TX , abstract 3093, 2009

Mayer IA, Means-Powell J, Shyr Y, Arteaga CL. A phase Ib trial of Erlotinib, and EGFR inhibitor, and Everolimus (RAD001), an mTOR inhibitor, in patients with metastatic breast cancer. 32nd Annual San Antonio Breast Symposium, San Antonio, TX , abstract 3094, 2009

Mayer, IA. Treatment of HER2-positive metastatic breast cancer following initial progression. Clin Breast Cancer, 9 Suppl 2, S50-7, 2009

Planey, CR, Welch, EB, Xu, L, Chakravarthy, AB, Gatenby, JC, Freehardt, D, Mayer, I, Meszeoly, I, Kelley, M, Means-Powell, J, Gore, JC, Yankeelov, TE. Temporal sampling requirements for reference region modeling of DCE-MRI data in human breast cancer. J Magn Reson Imaging, 30(1), 121-34, 2009 PMCID:2782711

Pohlmann, PR, Mayer, IA, Mernaugh, R. Resistance to Trastuzumab in Breast Cancer. Clin Cancer Res, 15(24), 7479-7491, 2009

Guix, M, Granja, Nde M, Meszoely, I, Adkins, TB, Wieman, BM, Frierson, KE, Sanchez, V, Sanders, ME, Grau, AM, Mayer, IA, Pestano, G, Shyr, Y, Muthuswamy, S, Calvo, B, Krontiras, H, Krop, IE, Kelley, MC, Arteaga, CL. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. J Clin Oncol, 26(6), 897-906, 2008 PMCID:2614851

Guix, M, Mayer, IA, Meszoely, IM, Arteaga, CL. Evaluation of biological agents targeted at early-stage disease. Breast Cancer Res, 10 Suppl 4, S25, 2008 PMCID:2614851

Yankeelov, TE, Lepage, M, Chakravarthy, A, Broome, EE, Niermann, KJ, Kelley, MC, Meszoely, I, Mayer, IA, Herman, CR, McManus, K, Price, RR, Gore, JC. Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magn Reson Imaging, 25(1), 1-13, 2007 PMCID:2634832

Chakravarthy, AB, Kelley, MC, McLaren, B, Truica, CI, Billheimer, D, Mayer, IA, Grau, AM, Johnson, DH, Simpson, JF, Beauchamp, RD, Jones, C, Pietenpol, JA. Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer. Clin Cancer Res, 12(5), 1570-6, 2006

Mayer IA. Targeting Cytokine Receptors and Pathways in the Treatment of Breast Cancer. Cytokines and Cancer, chapter 10(Platanias LC (ed). 2005 Springer Science + Business Media, Inc.), 243, 2005

Mayer, IA. Targeting cytokine receptors and pathways in the treatment of breast cancer. Cancer Treat Res, 126, 243-62, 2005

Rouch D, Mayer I, Truica C . Barriers to chemoprevention of breast cancer with tamoxifen. American Society of Clinical Oncology Proceedings, 41th Annual Meeting , abst 1010, 2005

Chakravarthy B, Kelley M, McLaren B, Truica C, Mayer I, Brown C, Johnson K, Simpson J, Billheimer D, Pietenpol JA. Developing markers of therapeutic response using serial core biopsies to paclitaxel/radiation in stage II/III breast cancer . Breast Cancer Research and Treatment, supplement 1 (San Antonio Breast Cancer Symposium ? 27th Annual Meeting - Special Issue)(88), S50 (abstract 1028), 2004

Costa FP, Schemerling R, Costa OF, Costa PA, Albertotti C, Martins S, Buzaid AC, Maluf F, Mayer I, Marques R . Intra-hepatic lipiodol I-131 combined with oxaliplatin, infusional FUDR, leucovorin in hepatocarcinoma and hepatic metastasis. ASCO Proceedings, 40th Annual Meeting, Abstract No 4133, 2004

Mayer IA. Locally Advanced Breast Cancer. Manual de Oncologia Clinica - Hospital Sirio Libanes - Cutait R, Buzaid AC (eds). Rio de Janeiro: Reichmann & Affonso Editores, 2nd edition, chapter 2, 2004

Mayer IA. Metastatic Breast Cancer. Manual de Oncologia Clinica - Hospital Sirio Libanes - Cutait R, Buzaid AC (eds). Rio de Janeiro: Reichmann & Affonso Editores, 2nd edition, chapter 3, 2004

Yamaguchi NH, Mayer IA, Malzyner A, Andrade CJC, Murad AM, Giglio AD, Cardoso H. . A pilot feasibility study of gefitinib (ZD1839) and celecoxib in metastatic GI tumors. ASCO Proceedings, 40th Annual Meeting, Abstract No 3086, 2004

Costa FC, Marques RJ, Mayer IA, Maluf FC, Martins SC, Cutait R, Buzaid AC. Irinotecan, Oxaliplatin and Raltitrexed every two weeks in untreated metastatic colorectal cancer patients. ASCO Proceedings , 38th Annual Meeting, Abstract No 2348, 2002

Grumbach, I M, Mayer, I A, Uddin, S, Lekmine, F, Majchrzak, B, Yamauchi, H, Fujita, S, Druker, B, Fish, E N, Platanias, L C. Engagement of the CrkL adaptor in interferon alpha signalling in BCR-ABL-expressing cells. Br J Haematol, 112(2), 327-36, 2001

Mayer, I A, Verma, A, Grumbach, I M, Uddin, S, Lekmine, F, Ravandi, F, Majchrzak, B, Fujita, S, Fish, E N, Platanias, L C. The p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells. J Biol Chem, 276(30), 28570-7, 2001

Mayer IA, Grumbach IM, Fujita S, Uddin S, Platanias LC. Activation of the p38 Map kinase pathway mediates the growth inhibitory effects of IFN-alpha in Chronic Myelogenous Leukemia. Blood, 96(11), Abstract No 1500, 2000

Uddin S, Lekmine F, Sharma N, Majchrzak B, Mayer I, Young PR, Bokoch GM, Fish EN, Platanias LC . The Rac1/p38 Map kinase pathway is required for IFN-alpha dependent transcriptional activation but not serine phosphorylation of STAT-proteins. J Biol Chem, 275(36), 27634-40, 2000


Postdoctoral Position Available
Yes

Postdoctoral Position Details
Not available

Updated Date
09/22/2014